FIELD: medicine.
SUBSTANCE: invention relates to the application of (3S)-4-{4-[3-(3-methylpiperidine-1-yl)propoxy]phenyl}pyridine 1-oxide or its pharmaceutically acceptable salt and/or solvate of the specified compound (A) or its salt for the treatment and/or prevention in humans of diseases selected from the following: Alzheimer's disease; attention disorder; insomnia and memory impairment; cognitive disorders in psychiatric pathologies; cognitive disorders, mood disorders and concentration disorders, especially in elderly patients; depressive or asthenic conditions; Parkinson's disease; obstructive sleep apnea syndrome; dementia with Lewy bodies; vascular dementia; dizziness; motion sickness; obesity; diabetes and metabolic syndrome; sleep disorders; stress; psychotropic disorders; epilepsy; depression; narcolepsy with or without cataplexy; disorders of hypothalamic-pituitary secretion, cerebral circulation and/or in the immune system; excessive daytime sleepiness, such as excessive daytime sleepiness and fatigue associated with Parkinson's disease, obstructive sleep apnea syndrome or dementia; and/or for facilitation of night work or for adaptation to a change of a time zone in healthy people; substance abuse, in particular alcohol abuse; prevention of withdrawal syndrome with substance abuse; attention disorders; post-stroke fatigue, mood disorders, concentration and cognitive disorders; cognitive disorders in autism; chronic pain and chronic fatigue; attention and concentration disorders in ADHD (attention deficit hyperactivity disorder) in adults or after a stroke, where the specified use includes the administration of the compound (A) or its pharmaceutically acceptable salts, and/or solvates of the specified salts or the specified compound (A) to an adult, with a dosage of a free base between 20 and 50 mcg per day (in terms of the compound (A) in the form of the free base).
EFFECT: new therapeutic application of H3-ligands.
12 cl, 38 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| H3-LIGAND TETRAHYDRATE, ITS PRODUCTION METHOD, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | 2018 |
|
RU2771753C2 |
| NOVEL PIPERIDINE DERIVATIVES | 2006 |
|
RU2417985C2 |
| CONDENSED 4-OXOPYRIMIDINE DERIVATIVE | 2005 |
|
RU2358969C2 |
| SALTS AND CRYSTALLINE FORMS | 2014 |
|
RU2654855C2 |
| NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | 2010 |
|
RU2567755C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING PYRIDONE DERIVATIVES | 2012 |
|
RU2585287C2 |
| NONSTEROIDAL MODULATORS OF GLUCOCORTICOID RECEPTORS FOR LOCAL DRUG DELIVERY | 2016 |
|
RU2731618C2 |
| AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | 2022 |
|
RU2803084C1 |
| NOVEL HETEROCYCLIC COMPOUND, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2018 |
|
RU2733384C1 |
| PIPERIZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | 2005 |
|
RU2369604C2 |
